Suppr超能文献

当代巨型肾和内脏动静脉瘘的处理。

Contemporary management of giant renal and visceral arteriovenous fistulae.

机构信息

Division of Vascular and Endovascular Surgery, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.

出版信息

J Endovasc Ther. 2011 Dec;18(6):811-8. doi: 10.1583/11-3571.1.

Abstract

PURPOSE

To evaluate our experience with treatment of giant arteriovenous fistulae (AVFs) involving the renal and visceral vasculature and assess outcomes.

METHODS

Clinical data from 12 consecutive patients (10 women; median age 58 years, range 37-79) undergoing intervention for 14 giant renal/visceral AVFs over a 15-year period (1994-2008) were retrospectively reviewed. Only patients with extra-parenchymal, wide arteriovenous communications were included. Thirteen were located in the renal artery and one in the splenic artery. The etiology was most likely post-traumatic/iatrogenic in 6 patients, idiopathic in 4 (1 bilateral), congenital in 1 (bilateral), and one was associated with fibromuscular dysplasia. In 4 cases, the lesion was asymptomatic.

RESULTS

Two large renal AVFs were treated with open surgery: one elective AV fistula repair early in our experience and the other an emergent nephrectomy for rupture. Twelve AV fistulae were closed successfully using endovascular techniques performed solely through the feeding vessel without cannulating the draining vein. All symptomatic patients, except one with continued dyspnea from cardiac causes, had complete symptomatic relief. There was no mortality. Morbidity included 2 access site hematomas that were managed conservatively. Loss of renal parenchyma ranged from 5% to 30%, but median serum creatinine levels remained stable.

CONCLUSION

Endovascular treatment of giant renal/visceral AVFs is challenging but feasible and safe, with good organ preservation. Endovascular techniques have replaced open surgical repair as a first-line treatment for these challenging lesions.

摘要

目的

评估我们治疗累及肾和内脏血管的巨大动静脉瘘(AVF)的经验,并评估治疗结果。

方法

回顾性分析了 15 年间(1994 年至 2008 年)连续 12 例(10 例女性;中位年龄 58 岁,范围 37-79 岁)因 14 例巨大肾/内脏 AVF 接受介入治疗的患者的临床资料。仅纳入有实质外、广泛动静脉交通的患者。13 例位于肾动脉,1 例位于脾动脉。病因最有可能是 6 例创伤/医源性、4 例特发性(1 例双侧)、1 例先天性(双侧)和 1 例与纤维肌发育不良相关。4 例病变无症状。

结果

2 例大的肾 AVF 通过开放手术治疗:1 例是我们早期经验的择期动静脉瘘修复术,另 1 例是因破裂而紧急行肾切除术。通过仅经供血血管而不插管引流静脉,成功地通过血管内技术闭合了 12 例 AVF。除了 1 例因心脏原因持续呼吸困难的患者外,所有有症状的患者均完全缓解症状。无死亡病例。并发症包括 2 例经血管入路血肿,均保守治疗。肾实质损失范围为 5%至 30%,但中位数血清肌酐水平保持稳定。

结论

血管内治疗巨大肾/内脏 AVF 具有挑战性,但可行且安全,可良好保留器官。血管内技术已取代开放手术修复,成为这些具有挑战性病变的一线治疗方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验